NYSE:UNH 15 December 2025 - 29 December 2025

UnitedHealth Group Incorporated is trading in a quiet, post-Christmas U.S. session where stocks are hovering near record territory and volumes are lighter than normal. Against that backdrop, UNH shares were last at $330.09, up about 0.77% on the day, after trading between $326.44 and $330.94.

U.S. equities reopen on Friday, Dec. 26, 2025, after the Christmas holiday, and UnitedHealth Group Incorporated is heading into the session with a news-heavy backdrop that has moved the stock repeatedly this year: operational overhauls, federal scrutiny tied to Medicare billing practices, and shifting policy risk heading into 2026.

UnitedHealth Group Incorporated finished Tuesday, December 23, 2025 near the $325 level and traded modestly higher in after-hours, as investors head into a holiday-shortened Christmas Eve session with a heavy macro and policy calendar—but no major new company press release late Tuesday.

UnitedHealth Group Incorporated finished Monday’s session lower, even as the broader market pushed higher to start a holiday-shortened week. After the closing bell on December 22, 2025, trading in UNH was muted, suggesting investors largely stayed in “wait-and-see” mode heading into Tuesday’s open—focused less on a single new headline and more on the company’s ongoing operational reset, regulatory scrutiny, and what the next few catalysts could bring. Yahoo Finance+2Healthcare Dive+2

December 22, 2025 — UnitedHealth Group Incorporated is ending the year with investors focused less on “normal” quarterly momentum and more on a three-part storyline that could shape how the market values the healthcare giant in 2026: management’s operational overhaul after independent reviews, a heavy regulatory and legal backdrop, and the next earnings call—when the company will finally lay out full-year 2026 guidance.

As of December 21, 2025, UnitedHealth Group Incorporated heads into a holiday-shortened trading week with investors balancing a familiar mix of catalysts: regulatory and political headlines, ongoing scrutiny of Medicare Advantage practices, legal overhangs tied to Optum, and a fresh push by management to reset trust through an unusually public “fix-it” program. Reuters+1

UnitedHealth Group Incorporated heads into the weekend with investors weighing two powerful storylines: fresh political pressure on health insurance premiums and a company-led operational overhaul sparked by outside audits. The stock last closed at $327.42 on Friday, Dec. 19, down 0.22% on the day. It’s down about 33% over the past 12 months and down roughly 34% year-to-date, though it’s up modestly over the past month—a sign that bargain-hunters are starting to test the waters after a bruising 2025 for managed-care names. Finance Charts

NEW YORK — December 19, 2025 — UnitedHealth Group Incorporated finished Friday’s session close to flat after a sharp, headline-driven swing, then drifted modestly in after-hours trading. Two stories dominated the tape into the closing bell: President Donald Trump’s fresh push for insurers to cut prices/premiums, and UnitedHealth’s release of early findings from an independent review program that laid out 23 operational “action plans” and a timeline into early 2026. Reuters+2UnitedHealth Group+2

UnitedHealth Group Incorporated stock is ending a volatile 2025 with fresh headline risk—and a handful of potentially meaningful catalysts—front and center on December 18, 2025. Shares traded around $326–$327 in midday trading, after moving between roughly $324.66 and $330.50 intraday.

UnitedHealth Group Incorporated is ending Wednesday’s session on a cautious note, with shares slipping further after the closing bell as investors weigh a major investigative report, a risk-off tape in U.S. equities, and a busy macro calendar set to hit before Thursday’s open.

UnitedHealth Group Incorporated is back in focus for investors as the health insurance giant heads into a catalyst-heavy stretch: a dividend payment landing today, a confirmed date for full‑year 2025 results and 2026 guidance, and a drumbeat of regulatory and legal headlines tied to its Optum business and Medicare-related scrutiny.